Work

SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial

Year: 2004

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2004.22.14_suppl.4500

Authors: R. J. Motzer, B. I. Rini, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. A. Figlin, J. Zhu, S. T. Kim, C. Baum

Institutions: Fox Chase Cancer Center, Memorial Sloan Kettering Cancer Center, University of Wisconsin–Madison, University of California, San Francisco, Pfizer (United States), University of Michigan, Massachusetts General Hospital

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2605028478

Cites:

Cited by: 70

Related to: 10